2004, Data, DEA and Extraction - Medical Cannabis Brief

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2004

Data

DEA

Extraction

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

However, there are indications from studies done with cannabidiol-rich cannabis extracts in Israel that indicate that less side effects (46%) are achieved with a natural cannabis plant extract containing a 20:1 ratio of CBD to THC. The CBD-rich extract group had a lower effective dose on average, 6.1

Extraction

Extraction Pharmaceutical CBD Epilepsy

Further Consideration of the STATES Act

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2003, 2004, 2007, 2008, Nov. cocaine, its salts, optical and geometric isomers , and salts of isomers ; .

Banking

Banking Law Marijuana State Laws

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Further Consideration of the STATES Act

Stay Connected